NEW YORK–(BUSINESS WIRE)–Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”), which owns 27.5% of the outstanding common stock of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), today issued the following statement reg…
Author: Business Wire
Sydnexis Receives Complete Response Letter from FDA for SYD-101 to Slow Pediatric Myopia Progression
DEL MAR, Calif.–(BUSINESS WIRE)–Sydnexis, Inc., (www.sydnexis.com), a biopharmaceutical company focused on pediatric progressive myopia (PPM), today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL…
Alcon and STAAR Surgical Announce Adjournment of STAAR Special Meeting of Stockholders
GENEVA & LAKE FOREST, Calif.–(BUSINESS WIRE)–Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ: STAA), the manufacturer of the Implantable Collamer® Lens (ICL), today …
NextGen Healthcare and Eyefinity Align to Expand Offerings for Optometrists and Ophthalmologists
RANCHO CORDOVA, Calif.–(BUSINESS WIRE)– #NextGenHealthcare–NextGen Healthcare, a leading provider of innovative, cloud-based healthcare technology solutions, today announced the enhancement of its offerings for optometrists and ophthalmologists thro…
Global Healthy Living Foundation Leads Nationwide Recognition of Giant Cell Arteritis Awareness Day on October 23
UPPER NYACK, N.Y.–(BUSINESS WIRE)– #arthritis–Giant Cell Arteritis, an inflammatory blood vessel condition, gets recognition day October 23
Foster Grant Releases New Wicked: For Good – Inspired Eyewear
SMITHFIELD, R.I.–(BUSINESS WIRE)–Foster Grant, one of the world’s leading over-the-counter eyewear brands, has unveiled the second installment of its Wicked x Foster Grant collection, ahead of the upcoming release of Universal Pictures’ epic conclusi…
National Vision Holdings, Inc. Announces Third Quarter 2025 Earnings Release and Conference Call
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) will report its third quarter 2025 financial results before the market opens on Wednesday, November 5, 2025, and will host a conference call…
Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today announced the pricing of …
Viridian Therapeutics Announces Proposed Underwritten Public Offering
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today announced that it has com…
Cade Prize for Inventivity Announces 2025 Winners
GAINESVILLE, Fla.–(BUSINESS WIRE)– #CadePrize–Named after Dr. James Robert Cade, the lead inventor of Gatorade, the Cade Prize for Inventivity celebrates early-stage companies with innovative ideas and commercial potential. On Tuesday, October 14, f…
IntelePeer Introduces SmartAnalytics Starter Pack to Accelerate AI Adoption and Measurably Improve Business and Patient Outcomes
DANIA BEACH, Fla.–(BUSINESS WIRE)–IntelePeer, the trusted leader in AI-powered automation and analytics for customer and patient interactions, today introduced at HLTH 2025 the SmartAnalytics™ Starter Pack. The Pack gives multi-site healthcare organi…
Yunqi Capital Issues Letter to STAAR Surgical’s Board Calling for Timely Convening of the Special Meeting to Vote on the Alcon Transaction
HONG KONG–(BUSINESS WIRE)–Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ:STAA), today iss…
Science Corp.’s PRIMA BCI Implant Restores Functional Central Vision to Patients with Geographic Atrophy Caused By Age-Related Macular Degeneration, a Leading Cause of Blindness, The New England Journal of Medicine Reports
ALAMEDA, Calif.–(BUSINESS WIRE)–The New England Journal of Medicine (NEJM) today published a peer-reviewed original paper with the results of a landmark clinical trial demonstrating the efficacy of Science Corporation’s PRIMA brain-computer interface…
STAAR Surgical Announces Preliminary Net Sales Results for Third Quarter 2025
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced preliminary net sales results for the th…
Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potentially best-in-class medicines for serious and rare diseases, today announced it entered in…
Stoke Therapeutics Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy (ADOA)
BEDFORD, Mass.–(BUSINESS WIRE)–Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicines, today announced the presentation of two-year data from th…
Glaukos Announces FDA Approval of Epioxa™
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today the U…
Aurion Biotech Achieves All Primary, Secondary, and Exploratory Endpoints in AURN001 Phase 1/2 CLARA Trial at 12 Months
SEATTLE & CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)– #AAO2025–Aurion Biotech, a clinical-stage regenerative medicine company with a mission to restore vision to millions of patients, today announced positive 12 month results from the company’s Phase …
Genentech Presents New Phase III Pivotal Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today results from two Phase III studies evaluating the efficacy and safety of two doses of investigational vamikibart (0.25 an…
Diorasis Therapeutics Welcomes Dr. Dimitri Azar to Its Board of Directors
BOSTON–(BUSINESS WIRE)–Diorasis Therapeutics Welcomes Dr. Dimitri Azar to Its Board of Directors